| Year |
Citation |
Score |
| 2023 |
Powers N, Massena C, Crouse B, Smith M, Hicks L, Evans JT, Miller S, Pravetoni M, Burkhart D. Self-Adjuvanting TLR7/8 Agonist and Fentanyl Hapten Co-Conjugate Achieves Enhanced Protection against Fentanyl Challenge. Bioconjugate Chemistry. 34: 1811-1821. PMID 37758302 DOI: 10.1021/acs.bioconjchem.3c00347 |
0.338 |
|
| 2023 |
Crouse B, Miller SM, Muelken P, Hicks L, Vigliaturo JR, Marker CL, Guedes AGP, Pentel PR, Evans JT, LeSage MG, Pravetoni M. A TLR7/8 agonist increases efficacy of anti-fentanyl vaccines in rodent and porcine models. Npj Vaccines. 8: 107. PMID 37488109 DOI: 10.1038/s41541-023-00697-9 |
0.756 |
|
| 2023 |
Miller SM, Crouse B, Hicks L, Amin H, Cole S, Bazin HG, Burkhart DJ, Pravetoni M, Evans JT. A lipidated TLR7/8 adjuvant enhances the efficacy of a vaccine against fentanyl in mice. Npj Vaccines. 8: 97. PMID 37429853 DOI: 10.1038/s41541-023-00694-y |
0.382 |
|
| 2023 |
Martinez S, Harris H, Chao T, Luba R, Pravetoni M, Comer SD, Jones JD. The potential role of opioid vaccines and monoclonal antibodies in the opioid overdose crisis. Expert Opinion On Investigational Drugs. 1-5. PMID 36863002 DOI: 10.1080/13543784.2023.2187286 |
0.354 |
|
| 2023 |
Triller G, Vlachou EP, Hashemi H, van Straaten M, Zeelen JP, Kelemen Y, Baehr C, Marker CL, Ruf S, Svirina A, Chandra M, Urban K, Gkeka A, Kruse S, Baumann A, ... ... Pravetoni M, et al. A trypanosome-derived immunotherapeutics platform elicits potent high-affinity antibodies, negating the effects of the synthetic opioid fentanyl. Cell Reports. 42: 112049. PMID 36719797 DOI: 10.1016/j.celrep.2023.112049 |
0.729 |
|
| 2022 |
Crouse B, Wu MM, Gradinati V, Kassick AJ, Song D, Jahan R, Averick S, Runyon S, Comer SD, Pravetoni M. Efficacy and Selectivity of Monovalent and Bivalent Vaccination Strategies to Protect against Exposure to Carfentanil, Fentanyl, and Their Mixtures in Rats. Acs Pharmacology & Translational Science. 5: 331-343. PMID 35592436 DOI: 10.1021/acsptsci.1c00260 |
0.333 |
|
| 2022 |
Hamid FA, Marker CL, Raleigh MD, Khaimraj A, Winston S, Pentel PR, Pravetoni M. Pre-clinical safety and toxicology profile of a candidate vaccine to treat oxycodone use disorder. Vaccine. 40: 3244-3252. PMID 35469698 DOI: 10.1016/j.vaccine.2022.03.053 |
0.737 |
|
| 2022 |
Baehr CA, Wu MM, Pandit SG, Arias-Umana J, AuCoin D, Pravetoni M. . The Journal of Pharmacology and Experimental Therapeutics. PMID 35153198 DOI: 10.1124/jpet.121.001048 |
0.309 |
|
| 2021 |
Crouse B, Zhang L, Robinson C, Ban Y, Vigliaturo JR, Roy S, Pravetoni M. Housing conditions and microbial environment do not affect the efficacy of vaccines for treatment of opioid use disorders in mice and rats. Human Vaccines & Immunotherapeutics. 1-10. PMID 34411500 DOI: 10.1080/21645515.2021.1954442 |
0.367 |
|
| 2021 |
Huseby Kelcher AM, Baehr CA, Hamid FA, Hart GT, Pravetoni M. Contribution of Antibody-Mediated Effector Functions to the Mechanism of Efficacy of Vaccines for Opioid Use Disorders. Journal of Immunology (Baltimore, Md. : 1950). PMID 34281999 DOI: 10.4049/jimmunol.2100204 |
0.309 |
|
| 2021 |
Raleigh MD, King SJ, Baruffaldi F, Saykao A, Hamid FA, Winston S, LeSage MG, Pentel PR, Pravetoni M. Pharmacological mechanisms underlying the efficacy of antibodies generated by a vaccine to treat oxycodone use disorder. Neuropharmacology. 108653. PMID 34126123 DOI: 10.1016/j.neuropharm.2021.108653 |
0.332 |
|
| 2020 |
Robinson C, Gradinati V, Hamid F, Baehr C, Crouse B, Averick S, Kovaliov M, Harris D, Runyon S, Baruffaldi F, LeSage M, Comer S, Pravetoni M. Therapeutic and Prophylactic Vaccines to Counteract Fentanyl Use Disorders and Toxicity. Journal of Medicinal Chemistry. PMID 33215913 DOI: 10.1021/acs.jmedchem.0c01042 |
0.326 |
|
| 2020 |
Baehr CA, Huseby Kelcher A, Khaimraj A, Reed DE, Pandit SG, AuCoin D, Averick S, Pravetoni M. Monoclonal antibodies counteract opioid-induced behavioral and toxic effects in mice and rats. The Journal of Pharmacology and Experimental Therapeutics. PMID 32980813 DOI: 10.1124/jpet.120.000124 |
0.366 |
|
| 2020 |
Raleigh MD, Accetturo C, Pravetoni M. Combining a candidate vaccine for opioid use disorders with extended-release naltrexone increases protection against oxycodone-induced behavioral effects and toxicity. The Journal of Pharmacology and Experimental Therapeutics. PMID 32586850 DOI: 10.1124/Jpet.120.000014 |
0.496 |
|
| 2020 |
Gradinati V, Baruffaldi F, Abbaraju S, Laudenbach M, Amin R, Gilger B, Velagaleti P, Pravetoni M. Polymer-mediated delivery of vaccines to treat opioid use disorders and to reduce opioid-induced toxicity. Vaccine. PMID 32439214 DOI: 10.1016/J.Vaccine.2020.05.027 |
0.448 |
|
| 2020 |
Pravetoni M. Is the opioid use disorder epidemic impacting our immunological health? Brain, Behavior, and Immunity. PMID 32283290 DOI: 10.1016/J.Bbi.2020.04.022 |
0.325 |
|
| 2020 |
Lefevre EM, Pisansky MT, Toddes C, Baruffaldi F, Pravetoni M, Tian L, Kono TJY, Rothwell PE. Interruption of continuous opioid exposure exacerbates drug-evoked adaptations in the mesolimbic dopamine system. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 32079024 DOI: 10.1038/S41386-020-0643-X |
0.405 |
|
| 2020 |
Baehr C, Kelcher AH, Robinson C, Crouse B, Pravetoni M. Monoclonal Antibodies against Fentanyl and Fentanyl Analogs for Prevention of Opioid Overdose The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.05425 |
0.387 |
|
| 2020 |
Raleigh MD, King SJ, Saykao AT, Baruffaldi F, Gradinati V, Winston S, Pentel PR, Pravetoni M. Functional
in vivo
characteristics of antibodies generated by an oxycodone vaccine The Faseb Journal. 34: 1-1. DOI: 10.1096/Fasebj.2020.34.S1.03354 |
0.351 |
|
| 2019 |
Fulenwider HD, Nennig SE, Hafeez H, Price ME, Baruffaldi F, Pravetoni M, Cheng K, Rice KC, Manvich DF, Schank JR. Sex differences in oral oxycodone self-administration and stress-primed reinstatement in rats. Addiction Biology. e12822. PMID 31830773 DOI: 10.1111/Adb.12822 |
0.352 |
|
| 2019 |
Pravetoni M, Comer SD. Development of vaccines to treat opioid use disorders and reduce incidence of overdose. Neuropharmacology. PMID 31173759 DOI: 10.1016/J.Neuropharm.2019.06.001 |
0.438 |
|
| 2019 |
Baruffaldi F, Raleigh MD, King S, Roslawski M, Birnbaum A, Hassler C, Carroll FI, Runyon SP, Winston S, Pentel PR, Pravetoni M. Formulation and characterization of conjugate vaccines to reduce opioid use disorders suitable for pharmaceutical manufacturing and clinical evaluation. Molecular Pharmaceutics. PMID 31018096 DOI: 10.1021/Acs.Molpharmaceut.8B01296 |
0.38 |
|
| 2019 |
Robinson C, Baehr C, Schmiel SE, Accetturo C, Mueller DL, Pravetoni M. Alum adjuvant is more effective than MF59 at prompting early germinal center formation in response to peptide-protein conjugates and enhancing efficacy of a vaccine against opioid use disorders. Human Vaccines & Immunotherapeutics. PMID 30625019 DOI: 10.1080/21645515.2018.1558697 |
0.469 |
|
| 2019 |
Baehr C, Pravetoni M. Vaccines to treat opioid use disorders and to reduce opioid overdoses. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 44: 217-218. PMID 30405185 DOI: 10.1038/S41386-018-0197-3 |
0.442 |
|
| 2018 |
Raleigh MD, Baruffaldi F, Peterson SJ, Le Naour M, Harmon TM, Vigliaturo JR, Pentel PR, Pravetoni M. Vaccination reduces fentanyl distribution to the brain and fentanyl-induced toxicity in mice and rats: a potential role for a prophylactic vaccine against fentanyl-induced overdose. The Journal of Pharmacology and Experimental Therapeutics. PMID 30409833 DOI: 10.1124/Jpet.118.253674 |
0.449 |
|
| 2018 |
Baruffaldi F, Huseby Kelcher A, Laudenbach M, Gradinati V, Limkar A, Roslawski M, Birnbaum A, Lees A, Hassler C, Runyon SP, Pravetoni M. Pre-clinical efficacy and characterization of candidate vaccines for treatment of opioid use disorders using clinically viable carrier proteins. Molecular Pharmaceutics. PMID 30240216 DOI: 10.1021/Acs.Molpharmaceut.8B00592 |
0.46 |
|
| 2018 |
Laudenbach M, Baruffaldi F, Robinson C, Carter P, Seelig D, Baehr C, Pravetoni M. Blocking interleukin-4 enhances efficacy of vaccines for treatment of opioid abuse and prevention of opioid overdose. Scientific Reports. 8: 5508. PMID 29615715 DOI: 10.1038/S41598-018-23777-6 |
0.466 |
|
| 2018 |
Raleigh MD, Laudenbach M, Baruffaldi F, Peterson SJ, Roslawski MJ, Birnbaum AK, Carroll FI, Runyon SP, Winston S, Pentel PR, Pravetoni M. Opioid dose- and route-dependent efficacy of oxycodone and heroin vaccines in rats. The Journal of Pharmacology and Experimental Therapeutics. PMID 29535156 DOI: 10.1124/Jpet.117.247049 |
0.397 |
|
| 2017 |
Raleigh MD, Peterson SJ, Laudenbach M, Baruffaldi F, Carroll FI, Comer SD, Navarro HA, Langston TL, Runyon SP, Winston S, Pravetoni M, Pentel PR. Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse. Plos One. 12: e0184876. PMID 29194445 DOI: 10.1371/Journal.Pone.0184876 |
0.488 |
|
| 2016 |
Pravetoni M. Biologics to treat substance use disorders: current status and new directions. Human Vaccines & Immunotherapeutics. 0. PMID 27441896 DOI: 10.1080/21645515.2016.1212785 |
0.351 |
|
| 2015 |
Laudenbach M, Tucker AM, Runyon SP, Carroll FI, Pravetoni M. The frequency of early-activated hapten-specific B cell subsets predicts the efficacy of vaccines for nicotine dependence. Vaccine. 33: 6332-9. PMID 26409811 DOI: 10.1016/J.Vaccine.2015.09.015 |
0.365 |
|
| 2015 |
Laudenbach M, Baruffaldi F, Vervacke JS, Distefano MD, Titcombe PJ, Mueller DL, Tubo NJ, Griffith TS, Pravetoni M. The Frequency of Naive and Early-Activated Hapten-Specific B Cell Subsets Dictates the Efficacy of a Therapeutic Vaccine against Prescription Opioid Abuse. Journal of Immunology (Baltimore, Md. : 1950). 194: 5926-36. PMID 25972483 DOI: 10.4049/Jimmunol.1500385 |
0.41 |
|
| 2015 |
Kotecki L, Hearing M, McCall NM, Marron Fernandez de Velasco E, Pravetoni M, Arora D, Victoria NC, Munoz MB, Xia Z, Slesinger PA, Weaver CD, Wickman K. GIRK Channels Modulate Opioid-Induced Motor Activity in a Cell Type- and Subunit-Dependent Manner. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 35: 7131-42. PMID 25948263 DOI: 10.1523/Jneurosci.5051-14.2015 |
0.681 |
|
| 2015 |
Kotecki L, Hearing M, McCall NM, de Velasco EMF, Pravetoni M, Arora D, Victoria NC, Munoz MB, Xia Z, Slesinger PA, Weaver CD, Wickman K. GIRK channels modulate opioid-induced motor activity in a cell type- and subunit-dependent manner Journal of Neuroscience. 35: 7131-7142. DOI: 10.1523/JNEUROSCI.5051-14.2015 |
0.636 |
|
| 2014 |
Pravetoni M, Pentel PR, Potter DN, Chartoff EH, Tally L, LeSage MG. Effects of an oxycodone conjugate vaccine on oxycodone self-administration and oxycodone-induced brain gene expression in rats. Plos One. 9: e101807. PMID 25025380 DOI: 10.1371/Journal.Pone.0101807 |
0.397 |
|
| 2014 |
Pravetoni M, Vervacke JS, Distefano MD, Tucker AM, Laudenbach M, Pentel PR. Effect of currently approved carriers and adjuvants on the pre-clinical efficacy of a conjugate vaccine against oxycodone in mice and rats. Plos One. 9: e96547. PMID 24797666 DOI: 10.1371/Journal.Pone.0096547 |
0.444 |
|
| 2014 |
Taylor JJ, Laudenbach M, Tucker AM, Jenkins MK, Pravetoni M. Hapten-specific naïve B cells are biomarkers of vaccine efficacy against drugs of abuse. Journal of Immunological Methods. 405: 74-86. PMID 24462800 DOI: 10.1016/J.Jim.2014.01.010 |
0.394 |
|
| 2014 |
LeSage MG, Raleigh MD, Pravetoni M, Tally L, Pentel P. Effects of a morphine-conjugate vaccine on heroin self-administration in rats Drug and Alcohol Dependence. 140: e119. DOI: 10.1016/J.Drugalcdep.2014.02.341 |
0.396 |
|
| 2013 |
Cornish KE, de Villiers SH, Pravetoni M, Pentel PR. Immunogenicity of individual vaccine components in a bivalent nicotine vaccine differ according to vaccine formulation and administration conditions. Plos One. 8: e82557. PMID 24312662 DOI: 10.1371/Journal.Pone.0082557 |
0.348 |
|
| 2013 |
de Villiers SH, Cornish KE, Troska AJ, Pravetoni M, Pentel PR. Increased efficacy of a trivalent nicotine vaccine compared to a dose-matched monovalent vaccine when formulated with alum. Vaccine. 31: 6185-93. PMID 24176492 DOI: 10.1016/J.Vaccine.2013.10.051 |
0.364 |
|
| 2013 |
Pravetoni M, Le Naour M, Tucker AM, Harmon TM, Hawley TM, Portoghese PS, Pentel PR. Reduced antinociception of opioids in rats and mice by vaccination with immunogens containing oxycodone and hydrocodone haptens. Journal of Medicinal Chemistry. 56: 915-23. PMID 23249238 DOI: 10.1021/Jm3013745 |
0.464 |
|
| 2013 |
Raleigh MD, Pravetoni M, Harris AC, Birnbaum AK, Pentel PR. Selective effects of a morphine conjugate vaccine on heroin and metabolite distribution and heroin-induced behaviors in rats. The Journal of Pharmacology and Experimental Therapeutics. 344: 397-406. PMID 23220743 DOI: 10.1124/Jpet.112.201194 |
0.462 |
|
| 2012 |
Chen X, Pravetoni M, Bhayana B, Pentel PR, Wu MX. High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants. Vaccine. 31: 159-64. PMID 23123021 DOI: 10.1016/J.Vaccine.2012.10.069 |
0.344 |
|
| 2012 |
Pravetoni M, Raleigh MD, Le Naour M, Tucker AM, Harmon TM, Jones JM, Birnbaum AK, Portoghese PS, Pentel PR. Co-administration of morphine and oxycodone vaccines reduces the distribution of 6-monoacetylmorphine and oxycodone to brain in rats. Vaccine. 30: 4617-24. PMID 22583811 DOI: 10.1016/J.Vaccine.2012.04.101 |
0.462 |
|
| 2012 |
Pravetoni M, Le Naour M, Harmon TM, Tucker AM, Portoghese PS, Pentel PR. An oxycodone conjugate vaccine elicits drug-specific antibodies that reduce oxycodone distribution to brain and hot-plate analgesia. The Journal of Pharmacology and Experimental Therapeutics. 341: 225-32. PMID 22262924 DOI: 10.1124/Jpet.111.189506 |
0.461 |
|
| 2012 |
Pravetoni M, Keyler DE, Pidaparthi RR, Carroll FI, Runyon SP, Murtaugh MP, Earley CA, Pentel PR. Structurally distinct nicotine immunogens elicit antibodies with non-overlapping specificities. Biochemical Pharmacology. 83: 543-50. PMID 22100986 DOI: 10.1016/J.Bcp.2011.11.004 |
0.32 |
|
| 2010 |
Arora D, Haluk DM, Kourrich S, Pravetoni M, Fernández-Alacid L, Nicolau JC, Luján R, Wickman K. Altered neurotransmission in the mesolimbic reward system of Girk mice. Journal of Neurochemistry. 114: 1487-97. PMID 20557431 DOI: 10.1111/J.1471-4159.2010.06864.X |
0.597 |
|
| 2010 |
Anderson GR, Cao Y, Davidson S, Truong HV, Pravetoni M, Thomas MJ, Wickman K, Giesler GJ, Martemyanov KA. R7BP complexes with RGS9-2 and RGS7 in the striatum differentially control motor learning and locomotor responses to cocaine. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. 35: 1040-50. PMID 20043004 DOI: 10.1038/Npp.2009.212 |
0.614 |
|
| 2008 |
Perry CA, Pravetoni M, Teske JA, Aguado C, Erickson DJ, Medrano JF, Luján R, Kotz CM, Wickman K. Predisposition to late-onset obesity in GIRK4 knockout mice. Proceedings of the National Academy of Sciences of the United States of America. 105: 8148-53. PMID 18523006 DOI: 10.1073/Pnas.0803261105 |
0.738 |
|
| 2008 |
Cruz HG, Berton F, Sollini M, Blanchet C, Pravetoni M, Wickman K, Lüscher C. Absence and rescue of morphine withdrawal in GIRK/Kir3 knock-out mice. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 28: 4069-77. PMID 18400906 DOI: 10.1523/Jneurosci.0267-08.2008 |
0.655 |
|
| 2008 |
Pravetoni M, Wickman K. Behavioral characterization of mice lacking GIRK/Kir3 channel subunits. Genes, Brain, and Behavior. 7: 523-31. PMID 18194467 DOI: 10.1111/J.1601-183X.2008.00388.X |
0.625 |
|
| 2007 |
Anderson GR, Lujan R, Semenov A, Pravetoni M, Posokhova EN, Song JH, Uversky V, Chen CK, Wickman K, Martemyanov KA. Expression and localization of RGS9-2/G 5/R7BP complex in vivo is set by dynamic control of its constitutive degradation by cellular cysteine proteases. The Journal of Neuroscience : the Official Journal of the Society For Neuroscience. 27: 14117-27. PMID 18094251 DOI: 10.1523/Jneurosci.3884-07.2007 |
0.572 |
|
| Show low-probability matches. |